FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060163314> ?p ?o ?g. }

• W2060163314 endingPage "16573" @default.
• W2060163314 startingPage "16569" @default.
• W2060163314 abstract "Protein kinase CK2 has been implicated in the regulation of a wide range of proteins that are important in cell proliferation and differentiation. Here we demonstrate that the stress signaling agents anisomycin, arsenite, and tumor necrosis factor-α stimulate the specific enzyme activity of CK2 in the human cervical carcinoma HeLa cells by up to 8-fold, and this could be blocked by the p38 MAP kinase inhibitor SB203580. We show that p38α MAP kinase, in a phosphorylation-dependent manner, can directly interact with the α and β subunits of CK2 to activate the holoenzyme through what appears to be an allosteric mechanism. Furthermore, we demonstrate that anisomycin- and tumor necrosis factor-α-induced phosphorylation of p53 at Ser-392, which is important for the transcriptional activity of this growth suppressor protein, requires p38 MAP kinase and CK2 activities. Protein kinase CK2 has been implicated in the regulation of a wide range of proteins that are important in cell proliferation and differentiation. Here we demonstrate that the stress signaling agents anisomycin, arsenite, and tumor necrosis factor-α stimulate the specific enzyme activity of CK2 in the human cervical carcinoma HeLa cells by up to 8-fold, and this could be blocked by the p38 MAP kinase inhibitor SB203580. We show that p38α MAP kinase, in a phosphorylation-dependent manner, can directly interact with the α and β subunits of CK2 to activate the holoenzyme through what appears to be an allosteric mechanism. Furthermore, we demonstrate that anisomycin- and tumor necrosis factor-α-induced phosphorylation of p53 at Ser-392, which is important for the transcriptional activity of this growth suppressor protein, requires p38 MAP kinase and CK2 activities. casein kinase 5,6-dichlororibifuranosylbenzimidazole glutathioneS-transferase tumor necrosis factor polyacrylamide gel electrophoresis mititogen-activated protein kinase 4-morpholinepropanesulfonic acid The signaling pathways that regulated protein kinase CK21 (formerly casein kinase II) have been elusive since the discovery of this highly conserved and ubiquitous protein-serine/threonine kinase over 45 years ago (1.Burnett G. Kennedy E.P. J. Biol. Chem. 1954; 211: 969-980Abstract Full Text PDF PubMed Google Scholar, 2.Pinna L.A. Meggio F. Cell Cycle Res. 1997; 3: 77-96Crossref PubMed Scopus (313) Google Scholar, 3.Heriche J.K. Chambaz E.M. Oncogene. 1998; 17: 13-18Crossref PubMed Scopus (43) Google Scholar, 4.Guerra B. Issinger O.J. Electrophoresis. 1999; 20: 391-408Crossref PubMed Scopus (365) Google Scholar, 5.Dobrowolska G. Lozeman F.J. Li D. Krebs E.G. Mol. Cell. Biochem. 1999; 191: 3-12Crossref PubMed Google Scholar). Despite the identification of over 160 putative substrates for CK2, the overriding function of this kinase has been evasive. In most cells, the holoenzyme form of CK2 is a constitutively active heterotetramer of two catalytic α and/or α′) and two regulatory (β) subunits, but CK2β-free pools of CK2α also exist. Further increases (2–3-fold) in the phosphotransferase activity of CK2 in cell lysates toward synthetic peptide substrates have been reported following treatment of murine and human fibroblastic cell lines, A431 and 3T3-L1 adipocytes with serum (6.Carroll D. Marshak D.R. J. Biol. Chem. 1989; 264: 7345-7348Abstract Full Text PDF PubMed Google Scholar), insulin (7.Sommercorn J. Mulligan J.A. Lozeman F.J. Krebs E.G. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 8834-8838Crossref PubMed Scopus (186) Google Scholar, 8.Klarlund J.K. Czech M.P. J. Biol. Chem. 1988; 263: 15872-15875Abstract Full Text PDF PubMed Google Scholar, 9.Villa-Moruzzi E. Crabb J.W. Biochem. Biophys. Res. Commun. 1991; 177: 1019-1024Crossref PubMed Scopus (10) Google Scholar), insulin-like growth factor-18 (10.Wang L.G. Liu X.M. Wikiel H. Bloch A. J. Leukocyte Biol. 1995; 57: 332-334Crossref PubMed Scopus (15) Google Scholar), epidermal growth factor (7.Sommercorn J. Mulligan J.A. Lozeman F.J. Krebs E.G. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 8834-8838Crossref PubMed Scopus (186) Google Scholar, 11.Ackerman P. Osheroff N. J. Biol. Chem. 1989; 264: 11958-11965Abstract Full Text PDF PubMed Google Scholar), bombesin (12.Agostinis P. Van Lint J. Sarno S. De Witte P. Vandenheede J.R. Merlevede W. J. Biol. Chem. 1992; 267: 9732-9737Abstract Full Text PDF PubMed Google Scholar), and tumor necrosis factor (TNF) (13.Van Lint J. Agostinis P. Vandevoorde V. Haegeman G. Fiers W. Merlevede W. Vandenheede R.J. J. Biol. Chem. 1992; 267: 25916-25921Abstract Full Text PDF PubMed Google Scholar). CK2 phosphotransferase activity and protein levels are also commonly elevated in solid human tumors and transformed cell lines (2.Pinna L.A. Meggio F. Cell Cycle Res. 1997; 3: 77-96Crossref PubMed Scopus (313) Google Scholar, 3.Heriche J.K. Chambaz E.M. Oncogene. 1998; 17: 13-18Crossref PubMed Scopus (43) Google Scholar, 4.Guerra B. Issinger O.J. Electrophoresis. 1999; 20: 391-408Crossref PubMed Scopus (365) Google Scholar, 14.Prowald K. Fischer H. Issinger O.-G. FEBS Lett. 1984; 176: 479-483Crossref PubMed Scopus (74) Google Scholar, 15.Munstermann U. Friz G. Seitz G. Yiping L. Schneider H.R. Issinger O.-G. Eur. J. Biochem. 1990; 189: 251-257Crossref PubMed Scopus (192) Google Scholar). Furthermore, CK2α overexpression along with c-Myc induces lymphomas in mice (16.Seldin D.C. Leder P. Science. 1995; 267: 894-897Crossref PubMed Scopus (361) Google Scholar). While the increased expression of CK2 is linked with neoplastic transformation, little is known concerning acute regulation of this protein kinase. HeLa cells were grown at 37 °C on 125-cm2 flasks in M199 medium (Life Technologies, Inc.) supplemented with 10% fetal calf serum. For cell stimulation, HeLa cells were split at 2 × 106cells/10-cm2 dish 24 h prior to starvation. Cells were starved with 0.5% fetal calf serum for 15–20 h before exposure to stimuli. Starved cells were incubated with 10 μm SB203580 (Calbiochem) for 30 min prior to addition of 10 μg/ml anisomycin (Sigma) for 30 min, 50 μm arsenite (Sigma) for 15 min, or 20 ng/ml TNFα for 15 min. Adhering cells were washed twice with ice-cold phosphate-buffered saline, scraped, then lysed in 50 mm Hepes (pH 7.2), 100 mm NaCl, 1 mm EGTA, and 20 mm sodium fluoride in Buffer A (1 mm sodium orthovanadate, 1% aprotinin, 1 mmphenylmethylsulfonyl fluoride, 1 μm pepstatin, 0.5 μg/ml leupeptin, 10 μg/ml soybean trypsin inhibitor, and 1% Nonidet P-40). Lysates were subjected to brief sonication for 2 × 10 s, centrifuged at 15,000 rpm for 5 min, and the supernatants were collected and stored frozen prior to use. Protein was determined by the method of Bradford (17.Bradford M.M. Anal. Biochem. 1976; 72: 248-254Crossref PubMed Scopus (214351) Google Scholar) using bovine serum albumin as a standard. In some experiments, anisomycin-treated cells were lysed with ice-cold 100 mm Tris-HCl (pH 8), 100 mm NaCl, 50 mm MgCl2, 0.3 mm EDTA, 0.5 mm ZnCl2, and 1% Nonidet P-40. After sonication for 2 × 10 s, the lysates were centrifuged at 14,000 rpm for 5 min and the supernatant was incubated with 0.5 units/μg alkaline phosphatase (Calbiochem) for 2 h at 37 °C. Ten volumes of ice-cold Buffer B (10 mm MOPS (pH 7.2), 25 mm β-glycerophosphate, 2 mm EDTA, 5 mm EGTA, and 2 mm sodium orthovanadate) were added and the sample was subjected to MonoQ anion-exchange chromatography. Cell lysates (2 mg protein) were diluted 1:10 in Buffer B and loaded onto a MonoQ (1 ml; Amersham Pharmacia Biotech) column at 4 °C. The anion-exchange column was eluted with a 20-ml linear gradient of 0–0.8 mNaCl in Buffer B and 0.5-ml fractions were collected. Immunoprecipitations were performed with a rabbit polyclonal antibody for p38α (Santa Cruz Biotechnology), and a mouse monoclonal antibody for CK2β. Cell extracts (0.5 mg) were precleared by incubation for 1 h with 20 μl of protein A-Sepharose, and then for 30 min with 20 μl of protein-A Sepharose that had been blocked with 1% bovine serum albumin. The precleared lysates were further incubated with 4 μg of the appropriate antibody and 20 μl of protein A-Sepharose in the presence of 0.1% SDS for 3 h at 4 °C. The beads were washed four times with 20 mm Tris-HCl (pH 7.4) and 150 mm NaCl in Buffer A. CK2 activity following column chromatography was assayed when 5 μl of MonoQ fractions were incubated in a final volume of 25 μl with 5 μg of partially phosphorylated casein and 100 μm[γ-32P]ATP (2.5 μCi/assay) in Buffer C (12 mm MOPS (pH 7.2), and 15 mm MgCl2) for 10 or 15 min at 30 °C. These and other CK2 assays were performed in the absence and presence of either 20 μg/ml heparin (Sigma), 20 μm DRB (Sigma) or 20 μm SB203580 (CalBiochem). In cytosolic extracts, CK2 activity was assayed with 0.5 mm substrate peptide RRADDSDDDDD (Calbiochem). The phosphorylation of casein was quantitated by spotting 20 μl on to a 1.5-cm2 piece of Whatman P-81 phosphocellulose paper. The papers were washed extensively in 1% (w/v) phosphoric acid, transferred into 6-ml plastic vials containing 0.5 ml of Ecolume (ICN) scintillation fluid, and the incorporated radioactivity was measured in Wallac (LKB) scintillation counter. For immune complex kinase assays, immunoprecipitated beads were washed with Buffer C and incubated with 5 μg of casein in a final volume of 25 μl with 5 μCi of 100 μm [γ-32P]ATP in Buffer C for 10 min at 30 °C. Reactions were stopped by either spotting 20 μl onto Whatman P-81 paper and the incorporated radioactivity was measured as described above, or by addition of SDS-PAGE sample buffer (18.Laemmli U.K. Nature. 1970; 227: 680-684Crossref PubMed Scopus (206602) Google Scholar). After boiling, the samples were subjected to SDS-PAGE for autoradiography with x-ray film or immunoblotting analysis. Western blotting was carried out with 0.1 to 1 μg/ml of the rabbit polyclonal antibodies: phospho-p38 (New England Biolabs), p38α (StressGen Biotechnologies), CK2α-III (19.Charlton L. Sanghera J.S. Clark-Lewis I. Pelech S.L. J. Biol. Chem. 1992; 267: 8840-8845Abstract Full Text PDF PubMed Google Scholar), CK2β (Kinetek Pharmaceuticals, Inc.), and phospho-p53 Ser-392 (New England Biolabs). Recombinant CK2 holoenzyme (Calbiochem) (1 μg) was incubated with 250 ng of the wild-type glutathione S-transferase (GST)-p38α or wild-type GST-Erk1 (Kinetek Pharmaceuticals, Inc.) in a final volume of 25 μl with 10 μCi of 100 μm[γ-32P]ATP in Buffer C for 15 min at 30 °C. Reactions were terminated by addition of SDS-PAGE sample buffer (18.Laemmli U.K. Nature. 1970; 227: 680-684Crossref PubMed Scopus (206602) Google Scholar). After SDS-PAGE, radioactivity incorporated into CK2 was detected by autoradiography. Either 2 μg of recombinant CK2 holoenzyme, CK2α or CK2β (Calbiochem) were mixed with 400 ng of GST-p38, GST, or GST-Erk1. The recombinant proteins were incubated for 1 h at 4 °C in Buffer D (12.5 mm MOPS (pH 7.2), 12.5 mm β-glycerophosphate, 0.5 mm EGTA, 7.5 mm MgCl2, and 0.5 mm sodium fluoride), and the GST was captured by addition of 25 μl of a 1:1 slurry of glutathione-Sepharose 4B beads for another hour at 4 °C. In some experiments, 20 μm SB203580, 20 μg/ml heparin, or 20 μm DRB was incubated with the GST-p38α or the recombinant CK2 for 15 min at 30 °C prior to the addition of the recombinant CK2 or GST-p38, respectively. The beads were washed 3 times with Buffer D containing 0.1% Nonidet P-40 and the bound proteins were eluted by addition of SDS-PAGE sample buffer. After boiling, the samples were subjected to SDS-PAGE on 12% acrylamide gels and immunoblotted with either CK2α-III (19.Charlton L. Sanghera J.S. Clark-Lewis I. Pelech S.L. J. Biol. Chem. 1992; 267: 8840-8845Abstract Full Text PDF PubMed Google Scholar) or CK2β antibodies. To explore the role of stress stimuli in the regulation of CK2, we investigated the effect of a 30-min treatment of serum-deprived HeLa cells with the protein synthesis inhibitor anisomycin. The casein phosphotransferase activity of CK2 was assessed following MonoQ fast protein liquid chromatography of the cell lysates. Anisomycin treatment caused an 8-fold activation of CK2, which eluted with 0.6 mNaCl in primarily fraction numbers 18 and 19 (Fig.1 A). This was confirmed by the sensitivity of the casein phosphotransferase activity peak to the CK2 inhibitor heparin (Fig. 1 A), and the elution of the α, α′, and β subunits of CK2 in these MonoQ fractions as revealed by immunoblotting analysis (Fig. 2,A and D). Exposure of the serum-starved cells to the mitochondrial oxidation inhibitor arsenite or the inflammatory cytokine TNF-α for 15 min was also observed to stimulate CK2 activity by 3–4-fold (Fig. 1 B). Furthermore, using a highly specific CK2 substrate peptide (RRADDSDDDDD), cytosolic extracts from HeLa cells treated with arsenite or anisomycin, respectively, contained 6.33 ± 0.06 and 7.44 ± 0.03 (mean ± S.E., n = 3) fold more phosphotransferase activity than was detectable with cytosol from non-treated cells (data not shown).Figure 2Phosphorylated and active p38 MAP kinase coelutes with CK2 from MonoQ. Following MonoQ fractionation of lysates from untreated (A, D, and G) HeLa cells or those exposed to anisomycin in the absence (B, E, andJ) and presence of 10 μm SB203580 (C, F, and I), there were no detectable changes in the distribution or amount of immunoreactive CK2 α- (A toC) and β-subunits (D to F). p38 eluted principally in the wash-through and CK2-containing fractions. Following anisomycin (10 μg/ml for 30 min) treatment of cells, the amount of p38 associated with CK2 was increased (H) as compared with untreated cells (G) or 10 μmSB203580-pretreated cells subsequently exposed to anisomycin (I). J, following incubation of lysates from anisomycin-treated cells with alkaline phosphatase (0.5 units/μg), most p38 eluted in the wash-through fractions from MonoQ.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Under the same conditions that activated CK2, anisomycin, arsenite, and TNF-α also produced marked increases in the phosphorylation of the p38 MAP kinase (also known as Hog, CSBP, MPK2, and SAPK2) as determined by immunoblotting with an antibody specific for the activating phosphorylation site of p38 isoforms (Fig. 1 C) (20.Paul A. Wilson S. Belham C.M. Robinson C.J.M. Scott M.H. Gould G.W. Plevin R. Cell Signal. 1997; 9: 403-410Crossref PubMed Scopus (285) Google Scholar). To assess whether a p38 MAP kinase mediated stress factor-induced activation of CK2, we took advantage of the specific p38 inhibitor SB203580 (21.Lee J.C. Laydon J.T. McDonnell P.C. Gallagher T.F. Kumar S. Green D. McNulty D. Blumenthal M.J. Heys R.J. Landvatter S.W. Strickler J.E. Mclaughlin M.M. Siemens I.R. Fisher S.M. Livi G.P. White J.R. Adams J.L. Young P.R. Nature. 1994; 372: 739-746Crossref PubMed Scopus (3128) Google Scholar, 22.Cuenda A. Rouse J. Doza Y.N. Meir R. Cohen P. Gallagher T.F. Young P.R. Lee J.C. FEBS Lett. 1995; 364: 229-233Crossref PubMed Scopus (1973) Google Scholar, 23.Goedert M. Cuenda A. Craxton M. Jakes R. Cohen P. EMBO J. 1997; 16: 3563-3571Crossref PubMed Scopus (354) Google Scholar, 24.Takenaka K. Moriguchi T. Nishida E. Science. 1998; 280: 599-602Crossref PubMed Scopus (243) Google Scholar). Treatment of the serum-deprived HeLa cells with SB203580 for 30 min prior to their exposure to anisomycin, arsenite, or TNFα abrogated the ability of each of these agents to stimulate CK2 (Fig. 1, A and B). As the anisomycin treatment consistently elicited the most striking activation of CK2, we exploited this agent to further explore the mechanism for the CK2 stimulation. There were no differences in the intensity of immunostaining of the α, α39, and β subunits of CK2 in serum-deprived anisomycin and SB203580-treated cells (Fig. 2, A-F). Consequently, the anisomycin appeared to increase the specific enzyme activity of CK2 without alteration of the α, α39/β subunit ratio or the total amount of CK2 protein. There were also no apparent reductions in the mobilities of the CK2 subunits following SDS-polyacrylamide gel electrophoresis of the MonoQ-fractionated lysates from cells exposed to anisomycin. Such retardation of CK2 subunits usually reflects their increased phosphorylation. CK2 subunits have been reported to interact with many other proteins (4.Guerra B. Issinger O.J. Electrophoresis. 1999; 20: 391-408Crossref PubMed Scopus (365) Google Scholar), including the protein kinases Mos, RafA, and Rsk, which bind to CK2β (25.Bozzetti M.P. Massari S. Finelli P. Meggio F. Boldyreff B. Issinger O.-G. Palumbo G. Ciriaco C. Bonaccorsi S. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 6067-6071Crossref PubMed Scopus (92) Google Scholar, 26.Hagemann C. Kalmes A. Wixler V. Wixler L. Schuster T. Rapp U.R. FEBS Lett. 1997; 403: 200-202Crossref PubMed Scopus (77) Google Scholar, 27.Boldyreff B. Issinger O.-G. FEBS Lett. 1997; 403: 197-199Crossref PubMed Scopus (93) Google Scholar, 28.Kusk M. Ahmed R. Thomsen B. Bendixen C. Issinger O.-G. Boldyreff B. Mol. Cell. Biochem. 1999; 191: 51-58Crossref PubMed Google Scholar). Therefore, we examined whether a p38 MAP kinase might directly associate with CK2. The peak of immunoreactivity of the α-isoform of p38 was found to coelute with CK2 following MonoQ fractionation, and this was most pronounced in lysates from anisomycin-treated cells (Fig. 2, G and H). By contrast, the amount of p38α coeluting with CK2 was substantially reduced in extracts from cells treated with both anisomycin and SB203580, and a large portion of the MAP kinase failed to bind to the MonoQ column and eluted in wash-through fractions 4–7 (Fig.2 I). An even more dramatic redistribution of p38α away from CK2 was produced when the lysates from cells exposed to anisomycin were incubated with alkaline phosphatase to dephosphorylate the p38α prior to MonoQ chromatography (Fig. 2 J). CK2 subunits were not detectable by immunoblotting in MonoQ fractions 4–7 neither before nor after alkaline phosphatase treatment. Furthermore, the alkaline phosphatase treatment abolished the anisomycin-induced activation of CK2 (data not shown). An implication of these experiments was that p38α MAP kinase must be in an active conformation in order to maximally bind and activate CK2. While the preceding data for CK2 and p38α residing in a common complex was only correlative, direct evidence was obtained through coimmunoprecipitation studies. The p38α antibody was used to immunoprecipitate equivalent amounts of p38α from lysates of serum-deprived, anisomycin-, and SB203580 + anisomycin-treated cells (Fig. 3 B). The casein phosphotransferase activity was approximately 4-fold higher in the immunocomplexes from anisomycin-treated as compared with untreated cells, and this was reduced to less than a 2-fold stimulation by the SB203580 (Fig. 3 A). These immunocomplexes with p38α antibody were shown to contain both the α and β subunits of CK2 by immunoblotting, and their presence was increased in the immunocomplexes from anisomycin-treated cells (Fig. 3, C and D). Reciprocally, in immunocomplexes obtained with an antibody specific for CK2β, p38α was largely immunodetected in samples from anisomycin-treated cells, with little if any evident in immunocomplexes from serum-starved or SB203580 + anisomycin-treated cells (Fig.3 E). Further support for the direct interaction of CK2 and p38α was obtained through the use of recombinant CK2 and partially active p38α expressed as a GST fusion protein. GST-p38 displayed binding for both α and β subunits of CK2 when they were expressed separately (data not shown). Therefore p38 can interact with both CK2 subunits independently. The interaction of CK2 for GST-p38α was specific, since no binding of CK2α was detected when either GST or GST fused to the MAP kinase Erk1 was substituted for GST-p38α (Fig.4 C). GST-p38 stimulated the casein phosphotransferase activity of recombinant CK2 by 2-fold, and this was sensitive to SB203580 and the CK2 inhibitors heparin and 5,6-dichloro-ribifuranosylbenzimidazole (DRB) (Fig. 4 A). When the CK2·GST-p38α complex immobilized on glutathione-Sepharose was incubated with [γ-32P]ATP, there was strong phosphorylation of the β-subunit of CK2 (Fig. 4 B), but not the α-subunit of CK2 (data not shown). This phosphorylation was abolished when the incubations with [γ-32P]ATP were carried out with SB203580, DRB, or heparin. When the presence of CK2α was ascertained by immunoblotting, the DRB and heparin did not dissociate the CK2·GST-p38α complex, whereas SB203580 did (Fig.4 C). These findings indicated that the radiolabeling of CK2β in the presence of GST-p38 was largely due to autophosphorylation, apparently from the stimulation of CK2 catalytic activity. This was further supported by experiments in which the CK2 was preincubated with unlabeled ATP for 15 min to saturate the autophosphorylation sites, and then with [γ-32P]ATP in the absence and presence of GST-p38α for an additional 10 min. Under these circumstances, there was no enhanced incorporation of radioactivity into the α and β subunits of CK2 with the addition of GST-p38α (data not shown). Collectively, our results support a model in which phosphorylated p38α is able to engage CK2 in a complex through direct interaction with both the α and β subunits of CK2. It would appear that an active conformation of p38α is needed for binding, since the SB203580 prevented complex formation. Through an allosteric effect exerted by active p38α, CK2 may become stimulated to phosphorylate other targets. It is unclear if the increased autophosphorylation of CK2 may be sufficient to preserve the state of activation of CK2 after p38α is dissociated. The ability of 4-fold lower levels of p38α to activate CK2 in vitro is consistent with this possibility. The functional consequences of the stress activating of CK2 may include activation of the p53 growth suppressor protein. Phosphorylation at Ser-392 in human p53 (equivalent to Ser-389 in murine p53) is known to increase its DNA binding ability and transcriptional activity (29.Hupp T.R. Lane D.P. Curr. Biol. 1994; 4: 865-875Abstract Full Text Full Text PDF PubMed Scopus (301) Google Scholar, 30.Sakaguchi K. Sakamoto H. Lewis M.S. Anderson C.W. Erickson J.W. Appella E. Xie D. Biochemistry. 1997; 36: 10117-10124Crossref PubMed Scopus (226) Google Scholar, 31.Kapor M. Lozano G. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 2834-2837Crossref PubMed Scopus (194) Google Scholar). Recently, Huang et al. (32.Huang C. Ma W.-Y. Maxiner A. Sun Y. Dong Z. J. Biol. Chem. 1999; 274: 12229-12235Abstract Full Text Full Text PDF PubMed Scopus (254) Google Scholar) have reported that the UV-induced phosphorylation of p53 at Ser-389, which is blocked by the p38 MAP kinase inhibitor SB202190 in vivo, is performed directly by p38 in vitro. Furthermore, p38 could be co-immunoprecipitated from cell lysates with p53 by using antibodies against p53 (32.Huang C. Ma W.-Y. Maxiner A. Sun Y. Dong Z. J. Biol. Chem. 1999; 274: 12229-12235Abstract Full Text Full Text PDF PubMed Scopus (254) Google Scholar). But Kraiss et al. (33.Kraiss S. Barnekow A. Montenarh M. Oncogene. 1990; 5: 845-855PubMed Google Scholar) have found that CK2 is also co-immunoprecipitated with p53. Our experiments support a model in which a p38·CK2 complex binds to p53, and the direct phosphorylation of Ser-389 in response to UV radiation is catalyzed by CK2. To test the hypothesis that the p53 is a downstream target of the stress stimuli anisomycin, arsenite, and TNFα, we performed immunoblotting studies of lysates from HeLa cells that had been treated with these factors using a p53 Ser-392 phosphorylation site-specific antibody. As shown in Fig. 5, the treatment of serum-deprived HeLa cells with any of these agents enhanced the phosphorylation of p53 at this site. The phosphorylation of p53 in response to anisomycin and TNFα, but not arsenite, was markedly attenuated by either DRB or SB203580. This indicated that the phosphorylation of p53 at an activating site in response to anisomycin or TNFα was mediated by p38 MAP kinase and CK2. In the case of arsenite, there may be an alternative pathway, in addition to the p38 MAP kinase-CK2 route, by which p53 can be phosphorylated at the Ser-392 site. The implication of CK2 in mediation of stress signaling downstream of p38 MAP kinase is a surprising outcome of our study. Our findings underline the importance of phosphatase inhibitors to preserve the state of CK2 activation and the potential influence of agents that are commonly used to inhibit cellular processes (e.g. protein synthesis, mitochondrial function, and cell cycle progression) in order to study the regulation and role of CK2." @default.
• W2060163314 created "2016-06-24" @default.
• W2060163314 creator A5011414937 @default.
• W2060163314 creator A5022311710 @default.
• W2060163314 creator A5047347436 @default.
• W2060163314 creator A5047661121 @default.
• W2060163314 creator A5084875396 @default.
• W2060163314 date "2000-06-01" @default.
• W2060163314 modified "2023-10-12" @default.
• W2060163314 title "Stress-induced Activation of Protein Kinase CK2 by Direct Interaction with p38 Mitogen-activated Protein Kinase" @default.
• W2060163314 cites W1482405769 @default.
• W2060163314 cites W1497489540 @default.
• W2060163314 cites W1501199419 @default.
• W2060163314 cites W1523300862 @default.
• W2060163314 cites W1527291914 @default.
• W2060163314 cites W1569942952 @default.
• W2060163314 cites W1641574298 @default.
• W2060163314 cites W1963995727 @default.
• W2060163314 cites W1964785626 @default.
• W2060163314 cites W1967724297 @default.
• W2060163314 cites W1970667125 @default.
• W2060163314 cites W1973428731 @default.
• W2060163314 cites W1997499490 @default.
• W2060163314 cites W2017101959 @default.
• W2060163314 cites W2022914311 @default.
• W2060163314 cites W2026084872 @default.
• W2060163314 cites W2032731042 @default.
• W2060163314 cites W2053500972 @default.
• W2060163314 cites W2068229957 @default.
• W2060163314 cites W2081115041 @default.
• W2060163314 cites W2088172210 @default.
• W2060163314 cites W2091821996 @default.
• W2060163314 cites W2095942428 @default.
• W2060163314 cites W2100837269 @default.
• W2060163314 cites W2102545675 @default.
• W2060163314 cites W2115746022 @default.
• W2060163314 cites W2123269248 @default.
• W2060163314 cites W2142540964 @default.
• W2060163314 cites W2183371117 @default.
• W2060163314 cites W4236531001 @default.
• W2060163314 cites W4252379536 @default.
• W2060163314 cites W4293247451 @default.
• W2060163314 doi "https://doi.org/10.1074/jbc.m000312200" @default.
• W2060163314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10747897" @default.
• W2060163314 hasPublicationYear "2000" @default.
• W2060163314 type Work @default.
• W2060163314 sameAs 2060163314 @default.
• W2060163314 citedByCount "140" @default.
• W2060163314 countsByYear W20601633142012 @default.
• W2060163314 countsByYear W20601633142013 @default.
• W2060163314 countsByYear W20601633142014 @default.
• W2060163314 countsByYear W20601633142015 @default.
• W2060163314 countsByYear W20601633142016 @default.
• W2060163314 countsByYear W20601633142017 @default.
• W2060163314 countsByYear W20601633142018 @default.
• W2060163314 countsByYear W20601633142019 @default.
• W2060163314 countsByYear W20601633142020 @default.
• W2060163314 countsByYear W20601633142021 @default.
• W2060163314 countsByYear W20601633142022 @default.
• W2060163314 countsByYear W20601633142023 @default.
• W2060163314 crossrefType "journal-article" @default.
• W2060163314 hasAuthorship W2060163314A5011414937 @default.
• W2060163314 hasAuthorship W2060163314A5022311710 @default.
• W2060163314 hasAuthorship W2060163314A5047347436 @default.
• W2060163314 hasAuthorship W2060163314A5047661121 @default.
• W2060163314 hasAuthorship W2060163314A5084875396 @default.
• W2060163314 hasBestOaLocation W20601633141 @default.
• W2060163314 hasConcept C124160383 @default.
• W2060163314 hasConcept C132149769 @default.
• W2060163314 hasConcept C137361374 @default.
• W2060163314 hasConcept C159479382 @default.
• W2060163314 hasConcept C161238802 @default.
• W2060163314 hasConcept C184235292 @default.
• W2060163314 hasConcept C185592680 @default.
• W2060163314 hasConcept C51551487 @default.
• W2060163314 hasConcept C55493867 @default.
• W2060163314 hasConcept C59143045 @default.
• W2060163314 hasConcept C82495950 @default.
• W2060163314 hasConcept C86803240 @default.
• W2060163314 hasConcept C90934575 @default.
• W2060163314 hasConcept C95444343 @default.
• W2060163314 hasConcept C97029542 @default.
• W2060163314 hasConcept C99405784 @default.
• W2060163314 hasConceptScore W2060163314C124160383 @default.
• W2060163314 hasConceptScore W2060163314C132149769 @default.
• W2060163314 hasConceptScore W2060163314C137361374 @default.
• W2060163314 hasConceptScore W2060163314C159479382 @default.
• W2060163314 hasConceptScore W2060163314C161238802 @default.
• W2060163314 hasConceptScore W2060163314C184235292 @default.
• W2060163314 hasConceptScore W2060163314C185592680 @default.
• W2060163314 hasConceptScore W2060163314C51551487 @default.
• W2060163314 hasConceptScore W2060163314C55493867 @default.
• W2060163314 hasConceptScore W2060163314C59143045 @default.
• W2060163314 hasConceptScore W2060163314C82495950 @default.
• W2060163314 hasConceptScore W2060163314C86803240 @default.
• W2060163314 hasConceptScore W2060163314C90934575 @default.
• W2060163314 hasConceptScore W2060163314C95444343 @default.
• W2060163314 hasConceptScore W2060163314C97029542 @default.

• next